论文部分内容阅读
医药行业属于典型的创新导向型行业,新药研发是医药企业核心竞争力的体现,由于我国医药行业整体缺乏新药创新能力,只能转向营销导向型,各企业之间竞争集中在同类产品的成本、营销力度、质量等方面。美国、日本和欧盟三分全球医药市场,同时他们正在开始新一轮新药研发领域的角力。为了扩展各自的利益,跨国间的大型公司重组合并已经基本完成,目前世界前10名的公司已经垄断了世界50％以上的市场。
The pharmaceutical industry is a typical innovation-oriented industry. The research and development of new drugs is the embodiment of the core competitiveness of pharmaceutical enterprises. Due to the lack of new drug innovation capability in the pharmaceutical industry as a whole, the pharmaceutical industry can only turn to the marketing-oriented type. The competition among enterprises is concentrated on the costs of similar products. Marketing efforts, quality and so on. The United States, Japan and the EU share a three-point global pharmaceutical market while they are starting a new round of wrestling in drug discovery. In order to expand their own interests, large-scale restructuring and cross-border mergers and acquisitions have been basically completed, the current top 10 companies in the world have monopolized more than 50% of the world market.